Improving Postoperative Analgesia After Functional Endoscopic Surgery

April 21, 2026 updated by: Ahmed Kamal Sayed, South Egypt Cancer Institute

Improving Postoperative Analgesia After Functional Endoscopic Surgery: Sphenopalatine Ganglion Block Versus Soaked Nasal Packing Using Bupivacaine and Dexmedetomidine

Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sara Mansour Mansour
  • Phone Number: 0020 1061092528
  • Email: saram@aun.edu.eg

Study Contact Backup

Study Locations

  • Egypt
      • Asyut, Egypt, 161715
        • Assiut university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age 18 - 60 years
  2. ASA physical status I -II
  3. Patients scheduled for elective FESS

Exclusion Criteria:

  1. Allergy to drugs used
  2. Coagulopathy or anticoagulant therapy
  3. Severe cardiovascular, renal and hepatic disease
  4. Chronic opioid use Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group a
Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
Experimental: druop b
Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia
Time Frame: 6 months
Numeric rating scale for pain will be assessed and recorded within the first 24 hours where 1 means the worst pain and 10 means no pain. Total rescue analgesia in 24 H when Numeric rating scale ≥ 4 was recorded and the first time when it was given will be recorded.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

South Egypt Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

October 30, 2026

Study Completion (Estimated)

October 30, 2026

Study Registration Dates

First Submitted

April 14, 2026

First Submitted That Met QC Criteria

April 21, 2026

First Posted (Actual)

April 29, 2026

Study Record Updates

Last Update Posted (Actual)

April 29, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 04-2026-300806

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe